Literature DB >> 11186241

Gastrointestinal first-pass effect of furosemide in rats.

E J Kim1, K S Han, M G Lee.   

Abstract

The first-pass effect of furosemide was investigated in rats. Furosemide intravenous solution (20 mg kg(-1) Lasix), was administered via the jugular vein and the portal vein, orally, and instilled directly into the duodenum of rats. The first-pass effects of furosemide by lung, heart, and liver seemed to be negligible in rats. The absolute bioavailability of furosemide was 28.9 and 48.3% after oral and intraduodenal administration, respectively. Based on the gastrointestinal (GI) recovery study, 68.3 and 69.5% of furosemide were found to have disappeared mainly due to absorption and/or metabolism from rat GI tract after oral and intraduodenal administration, respectively. The results indicate that gastrointestinal and intestinal first-pass effects of furosemide were approximately 40% (68.3-28.9%) and 20% (69.5-48.3%) of the dose, respectively.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11186241     DOI: 10.1211/0022357001777487

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  3 in total

1.  Pharmacokinetics of DA-7867, a new oxazolidinone, after intravenous or oral administration to rats: intestinal first-pass effect.

Authors:  Soo K Bae; Won-Suk Chung; Eun J Kim; Jae K Rhee; Jong W Kwon; Won B Kim; Myung G Lee
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

2.  Dose-dependent pharmacokinetics of itraconazole after intravenous or oral administration to rats: intestinal first-pass effect.

Authors:  Jee H Shin; Ka Y Choi; Yu C Kim; Myung G Lee
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

3.  Experimental Adjustment on Drug Interactions through Intestinal CYP3A Activity in Rat: Impacts of Kampo Medicines Repeat Administered.

Authors:  Natsumi Kinoshita; Yuriko Yamaguchi; Xiao-Long Hou; Kyoko Takahashi; Koichi Takahashi
Journal:  Evid Based Complement Alternat Med       Date:  2011-06-05       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.